Posts Tagged ‘stroke prevention’

November 19th, 2013

Another New Anticoagulant Works Well in AF Patients

Edoxaban, a direct oral factor Xa inhibitor, is the latest in the series of new oral anticoagulants seeking to take over the troubled role of warfarin in clinical practice. The results of ENGAGE-AF-TIMI 48 were presented at the American Heart Association meeting in Dallas and published simultaneously in the New England Journal of Medicine. In the trial, more than 21,000 […]

December 28th, 2012

FDA Approves Eliquis (Apixaban) for Stroke Prevention in AF

The FDA has finally approved apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). The action comes after the widely-anticipated drug had been plagued by delays at the FDA but well before the PDUFA deadline of March 17, 2013. Eliquis is the latest member […]

November 19th, 2012

Selections from Richard Lehman’s Literature Review: November 19th

This week’s topics include multivitamins and cancer prevention in men, a comparison of atorvastatin with or without a PCSK9 Antibody in primary hypercholesterolemia, type-2 diabetes screening and population mortality over 10 years, and more.

May 21st, 2012

Selections from Richard Lehman’s Literature Review: Week of May 21st

This week’s topics include warfarin vs. aspirin for stroke prevention in HF, CVD risks and azithromycin, coffee’s benefits, the old news that statins work, the question of HDL-C, abdominal aortic aneurysm, omega-3 fatty acid supplements, and Abbott’s methods for staying ahead with fenofibrate prescriptions.

March 14th, 2012

The $800 Million Gamble: Jumping Aboard or Jumping the Gun?


In the CLOSURE I trial (Evaluation of the STARFlex Septal Closure System in Patients with a Stroke and/or Transient Ischemic Attack Due to a Presumed Paradoxical Embolism through a Patent Foramen Ovale), 909 patients with a PFO who had a stroke or a transient ischemic attack (TIA) of unclear etiology were randomly assigned to device […]

November 16th, 2011

POWER to the People

Several Cardiology Fellows who are attending AHA.11 this week are blogging together on CardioExchange.  The Fellows include Revathi Balakrishnan, Eiman Jahangir, John Ryan (moderator), and Amit Shah. Read the previous post here. Check back often to learn about the biggest buzz in Orlando. Tuesday, I heard the presentation of the Practice-Based Opportunities for Weight Reduction (POWER) trial, […]

September 7th, 2011

Medical Therapy Wallops Stenting for Intracranial Stenosis

In recent years stenting for intracranial arterial stenosis has become widespread. Now, however, a trial testing the procedure has been terminated early, raising serious questions about both the safety and efficacy of the technique. In the SAMMPRIS (Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis) trial, which has now been published online […]

August 28th, 2011

ARISTOTLE Finds the Golden Mean of Anticoagulation

In ancient Greece the philosopher Aristotle thought the golden mean was the desirable middle between two extremes, one of excess and the other of deficiency. In cardiology, apixaban may be the golden mean of anticoagulation, achieving the ideal balance of reduced strokes and deaths without causing any additional bleeding complications. The Apixaban for Reduction in Stroke and Other […]

August 10th, 2011

Rivaroxaban Compared with Warfarin in 14,000 AF Patients

In ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), researchers tested rivaroxaban (20 mg/day) against warfarin in 14,264 patients with nonvalvular atrial fibrillation (AF). The results of the trial, which were first presented last November at the American […]

February 10th, 2011

Apixaban Better Than Aspirin for Stroke Prevention in AF Patients Unable to Take Warfarin

A new trial presented at the American Stroke Association’s International Stroke Conference and published online in the New England Journal of Medicine demonstrates that the novel factor Xa inhibitor apixaban is better than aspirin for the prevention of stroke in AF patients who are unable to take warfarin. Stuart Connolly and investigators in the AVERROES (Apixaban […]